For alpha-gal patients, allergy drug could cut the severity of reactions to red meat

Key Points:

• A study presented at the American College of Allergy, Asthma and Immunology meeting found that 95% of alpha-gal syndrome patients using the allergy drug omalizumab experienced significant reductions in allergic reaction frequency or severity, though the findings are not yet peer-reviewed.
• Alpha-gal syndrome, caused by a sugar molecule transmitted through lone star tick bites, triggers allergic reactions to red meat and some animal products, ranging from mild symptoms to life-threatening anaphylaxis.
• Omalizumab, approved for other severe food allergies, works by reducing IgE antibodies that drive allergic reactions, providing a safety layer that may reduce the severity of accidental exposures but does not cure the allergy.
• Eight study participants were able to reintroduce red meat, but researchers caution this does not confirm remission, as natural decreases in sensitivity may also play a role; further clinical trials are needed to clarify omalizumab’s long-term effects.
• With alpha-gal syndrome cases rising due to expanding tick populations, experts emphasize the importance of tick bite prevention and suggest omalizumab may be best used temporarily for patients with severe reactions and high IgE levels.